Two HIV-related treatment guidelines have been updated. "Guidelines for the Use of Antiretroviral Agents in HIV-Infected Adults and Adolescents," prepared by the U.S. Department of Health and Human Services and the Henry J. Kaiser Foundation Panel on Clinical Practices for Treatment of HIV Infection, has been updated several times since publication in MMWR.1 The most recent update contains information about the newly licensed nucleoside reverse transcriptase inhibitor, abacavir (Ziagen*).

In addition, the Working Group on Antiretroviral Therapy and Medical Management of HIV-Infected Children, comprising specialists caring for HIV-infected infants, children, and adolescents, has updated "Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection."2 These guidelines include information about the use of abacavir (Ziagen™) and the use of efavirenz (SustivaTM), a non-nucleoside reverse transcriptase inhibitor, for treating HIV infection in children. Also included is updated information about the newly available liquid preparation of nevirapine (Viramune™) for pediatric use.

The updates are available from the World-Wide Web site of the HIV/AIDS Treatment Information Service (ATIS) at http://www.hivatis.org,† or from ATIS, telephone (800) 448-0440.

*Use of trade names and commercial sources does not imply endorsement by the U.S. Department of Health and Human Services or CDC.

† References to sites of nonfederal organizations on the World-Wide Web are provided as a service to MMWR readers and do not constitute or imply endorsement of these organizations or their programs by CDC or the U.S. Department of Health and Human Services. CDC is not responsible for the content of pages found at these sites.